TABLE 2.
Type and Duration in Months of Therapy
| Regimen | After Weighting Cohort |
|---|---|
| BTKi Cohort (n = 181) | |
| Regimen name, No. (%) | |
| BTKi monotherapy | 160 (88.4) |
| BTKi + anti-CD20 | 17 (9.4) |
| Other BTKi regimens | 4 (2.2) |
| Subsequent therapy, % | 24.9 |
| Duration of treatment,a months, median (IQR) | 8.6 (4.3-16.6) |
| Duration of 2L,b months, median (IQR) | 11.6 (6.5-21.1) |
| Duration of follow-up,c months, median (IQR) | 16.0 (8.1-24.7) |
| Venetoclax Cohort (n = 98) | |
|---|---|
| Regimen name, No. (%) | |
| Venetoclax monotherapy | 36 (36.7) |
| Venetoclax + G | 38 (38.8) |
| Venetoclax + R | 23 (23.5) |
| Other venetoclax regimens | 1 (1.0) |
| Subsequent therapy, % | 19.4 |
| Duration of treatment,a months, median (IQR) | 8.2 (3.7-13.8) |
| Duration of 2L,b months, median (IQR) | 11.0 (5.9-21.6) |
| Duration of follow-up,c months, median (IQR) | 14.9 (7.9-24.6) |
Abbreviations: 2L, second-line; 3L, third-line; anti-CD20, monoclonal antibody directed against human CD20 antigen; BTKi, Bruton tyrosine kinase inhibitor; venetoclax + G, venetoclax + obinutuzumab; venetoclax + R, venetoclax + rituximab.
a
Difference in months between the index date and last claim for 2L plus days supplied.
b
Difference in months between the index date and earliest of 3L treatment or end of continuous enrollment.
c
Difference in months between the index date and the end of continuous enrollment.